目标：世界各地的癌症诊断日益增加。癌症死亡是最常见的死亡原因之一。获得抗癌药物是卫生政策的优先事项。本研究的目的是通过对土耳其药品定价中使用的人口增长、癌症发病率和固定欧元汇率 (FEE) 汇率参数进行建模，通过药盒销售数据评估抗癌药物的获取情况。方法：通过从 IQVIA 获得的药盒销售数据来评估抗癌药物的获取情况。盒子销售数据根据诊断代码 (ICD-10)、参考或一般状态进行分类。随着时间的推移，通过面板回归分析检查了抗癌药物的消费情况，同时考虑了土耳其人口增长、癌症发病率和药品定价中的费用率等变量。结果：2010年土耳其的癌症发病率为215.1，2017年为223.1（每十万）。虽然欧元实际汇率上涨了127.02%，但FEE费率却上涨了89.6%。采用回归方法，实际汇率差和固定汇率差 (RFED) 与参考和仿制药消费数据之间存在负相关关系。根据不同级别的诊断代码，药品获取受到影响。结直肠癌药物销售与每个变量（即汇率、人口增长和癌症发病率）呈负相关。相反，非小细胞肺癌与相关变量呈正相关。单克隆抗体等创新药组与蛋白激酶抑制剂的消耗呈现负相关。结论：根据我们的结果，定价策略可能是土耳其肿瘤药物的准入障碍。它应该审查有利于土耳其肿瘤药物获取的定价政策。版权所有 © 2024 Vural、Kaskati、Vural、Özalp 和 Gümüşel。

Objectives: Cancer diagnosis is increasing day by day all over the world. Deaths due to cancer are among the most common causes of death. Access to cancer drugs is a priority of health policies. The aim of this study is to evaluate access to cancer drugs through drug box sales data by modeling population growth, cancer incidence, and Fixed Euro Exchange (FEE) rate parameters used in drug pricing in Türkiye. Methods: Access to cancer drugs was evaluated by drug box sales figures obtained from IQVIA. Box sales data were classified according to diagnosis codes (ICD-10), reference, or generic status. Consumption of cancer drugs was examined over time with panel regression analysis, taking into account variables of population growth, cancer incidence, and the FEE rate in drug pricing in Türkiye. Results: The incidence of cancer in Türkiye was 215.1 in 2010 and 223.1 (per hundred thousand) in 2017. Whereas there was a 127.02% increase in the real euro exchange rate, there was an 89.6% increase in the FEE rate. With the regression approach, there is a negative relationship between the real and fixed exchange rate difference (RFED) and reference and generic drug consumption data. Medicine access is affected depending on diagnosis codes at different levels. Colorectal cancer medicine sales had negative correlations for each variable, namely, exchange rate, population growth, and cancer incidence. On the contrary, there was a positive correlation between non-small-cell lung cancer and relevant variables. Innovative medicine groups such as monoclonal antibodies and protein kinase inhibitor consumption showed a negative correlation. Conclusion: According to our results, pricing strategy may be an access barrier for oncology medicines in Türkiye. It should be reviewing the pricing policy that is beneficial for oncology medicine access in Türkiye.Copyright © 2024 Vural, Kaskati, Vural, Özalp and Gümüşel.